Just noticed STIM popped nearly 30% on their Q4 results - pretty solid numbers for a medical device company focused on depression and OCD treatment. Their NeuroStar system revenue jumped to $18.3M in Q4, up from $3.8M a year ago, and the clinic side doing the actual OCD stimming therapy sessions hit $23.5M. That's some serious traction. Full year revenue nearly doubled to $149.2M from $74.9M, though on an adjusted basis it's more like 15% growth year-over-year. They shipped 49 units in the quarter and ended the year with $34.1M in cash. CEO mentioned they actually hit positive operating cash flow last quarter, which is always a good sign. The NeuroStar Advanced Therapy System is basically their main revenue driver - it's a non-invasive treatment for major depressive disorder and OCD, and clearly demand is ramping up. Stock closed Tuesday at $1.46 before this premarket move. Curious to see if they can sustain this momentum when they release full financials on March 17. The OCD treatment space seems to be getting more attention, and this company's execution looks pretty tight so far.